Children’s Hospital GME Support Reauthorization Act of 2023
12/16/2024, 7:25 PMSummary of Bill HR 3887
Bill 118 hr 3887, also known as the Children’s Hospital GME Support Reauthorization Act of 2023, is a piece of legislation currently being considered by the US Congress. The purpose of this bill is to reauthorize funding for graduate medical education (GME) programs at children's hospitals across the country.The bill aims to ensure that children's hospitals have the necessary resources to train the next generation of pediatricians and other healthcare professionals. By reauthorizing funding for GME programs, the bill seeks to support the continued excellence of care provided by children's hospitals and ensure that they are able to meet the healthcare needs of children in their communities.
Specifically, the Children’s Hospital GME Support Reauthorization Act of 2023 would provide funding for GME programs at children's hospitals for a specified period of time. This funding would be used to support the training of medical residents and fellows in pediatric specialties, as well as to support research and other educational activities at children's hospitals. Overall, the bill aims to ensure that children's hospitals have the resources they need to continue providing high-quality care to children and to train the next generation of pediatric healthcare professionals. It is an important piece of legislation that has the potential to have a significant impact on the healthcare system in the United States.
Congressional Summary of HR 3887
Children's Hospital GME Support Reauthorization Act of 2023
This bill reauthorizes through FY2028 the Children's Hospital Graduate Medical Education Payment program, which supports education and training for medical residents and fellows in children's hospitals. The bill also bars children's hospitals that provide gender-affirming care to minors from receiving payments through the program.
Under the bill, gender-affirming care generally includes procedures (e.g., surgeries or hormone therapies) that change the body of an individual to correspond to a sex that is different than the individual's biological sex. It excludes, however, specified types of procedures, including those for treating (1) individuals who have both ovarian and testicular tissue or abnormal sex chromosome structure or hormones, or (2) infections or other harms that result from a previous gender-transition procedure.
